PARP1 and early-onset autosomal dominant Alzheimer disease: In addition, mutations in PARP1 genes have been associated with changes in the susceptibility and severity of Alzheimer’s disease; therefore, targeting NAD+ metabolism and PARP activity may be a therapeutic option in the treatment of neurodegenerative diseases.